Fusion Pharm (Fusion Pharm) Debt-to-EBITDA : 0.00 (As of . 20)

Fusion Pharm Debt-to-EBITDA Chart

Competitive Comparison of Fusion Pharm's Debt-to-EBITDA

For the Pharmaceutical Retailers subindustry, Fusion Pharm's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fusion Pharm's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Fusion Pharm's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Fusion Pharm's Debt-to-EBITDA falls into.

Fusion Pharm Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Fusion Pharm's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Fusion Pharm's annualized Debt-to-EBITDA for the quarter that ended in . 20 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (. 20) EBITDA data.

Fusion Pharm  (OTCPK:FSPM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Fusion Pharm Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Fusion Pharm's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusion Pharm (Fusion Pharm) Business Description